NCT06629428View on ClinicalTrials.gov

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
DRUG

Ublituximab

The participants will receive 48 weeks of treatment with ublituximab.

Trial Locations (2)

30303

Georgia State University, Atlanta

30327

Atlanta Neuroscience Institute, Atlanta

Sponsors
All Listed Sponsors
collaborator

Atlanta Neuroscience Institute

UNKNOWN

lead

Georgia State University

OTHER